



PATENT



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of

N. Leigh ANDERSON et al.

: Group Art Unit: 1652

Serial No.: 09/585,475

: Examiner: M. Walicka

Filed: 2 June 2000

For: PROTEIN MARKERS FOR PHARMACEUTICALS AND RELATED TOXICITY

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

In accordance with 37 C.F.R. §§ 1.56 and 1.97-1.98, Applicants hereby notify the Examiner of documents that may be deemed material to the examination of the above-identified application.

Since the instant Information Disclosure Statement is being filed prior to issuance of a first Office Action on the merits, no certification under 37 C.F.R. §1.97(e) or fee under 37 C.F.R. §1.17(b) is required.

Also, all of the documents are in English and therefore, no brief statement of relevance is required.


INFORMATION DISLCOSURE STATEMENT

N. Leigh ANDERSON et al.

U.S. Serial No.: 09/585,475

Applicants do not waive any right to take any action that would be appropriate to antedate or otherwise remove any listed document as a competent reference against the claims of the instant application.

Respectfully submitted,

  
Dean H. Nakamura  
Reg. No. 33,981

Roylance, Abrams, Berdo  
& Goodman, L.L.P.  
1300 19<sup>th</sup> Street, N.W., Suite 600  
Washington, D.C. 20036-2680  
(202) 659-9076

Dated: 07 December 2001